Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.6667.

GANX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Friday, December 19th. Maxim Group raised their target price on shares of Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Roth Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Gain Therapeutics in a report on Friday, December 19th. BTIG Research reissued a “buy” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GANX. Marshall Wace LLP lifted its stake in Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after acquiring an additional 80,407 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Gain Therapeutics in the third quarter valued at approximately $68,000. Virtu Financial LLC lifted its position in shares of Gain Therapeutics by 126.9% in the third quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after purchasing an additional 30,207 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Gain Therapeutics during the third quarter worth $47,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Gain Therapeutics in the third quarter valued at $28,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Trading Down 14.1%

Shares of NASDAQ GANX opened at $2.55 on Friday. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34. The stock has a market cap of $98.07 million, a price-to-earnings ratio of -4.18 and a beta of 0.06. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average is $2.99 and its 200-day moving average is $2.20.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). Equities research analysts predict that Gain Therapeutics will post -1 EPS for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.